United States Food and Drug Administration (USFDA) had indicated in February that they were resuming domestic inspections given the decline in COVID-19 cases. It also indicated that they would continue foreign and domestic critical inspections, which means that plants that really need to be inspected, would probably be inspected by the USFDA.
Recommended Articles
View All
Budget 2023: Pharma R&D, healthcare gets their due attention
Feb 1, 2023 IST4 Min(s) Read
Budget 2023 — Let the opposition use today's session effectively sans typical disruption tactics
Feb 1, 2023 IST5 Min(s) Read
Budget 2023: From improved GST structure to inverted duty reforms, the EV sector want a mega growth push
Jan 31, 2023 IST3 Min(s) Read
India's Economic Survey shifts the narrative to 'quality of life'
Jan 31, 2023 IST3 Min(s) Read
In January, they took a halt simply because of the Omicron variant. The USFDA has indicated that they plan to begin prioritised foreign inspections April onwards. So, USFDA inspections are going to pick up in the next couple of months or couple of weeks.
It has already picked up as Zydus Life’s injectable plant in Gujarat got inspected in February-March of 2022. They received three observations, but they also received approvals from that particular facility, so it's not really a concern anymore.
Watch the accompanying video of CNBC-TV18’s Ekta Batra for more details.